A low intravenous dose of pancreatic polypeptide reduced food intake by 11% and lowered hunger ratings in lean volunteers.
11% reduction in food intakeLean volunteers ate significantly fewer calories after receiving low-dose pancreatic polypeptide compared to placebo
What the researchers found
Intravenous infusion of pancreatic polypeptide (PP) at 5 pmol/kg per min — half the dose used in prior studies — reduced energy intake by 11% compared to saline in 14 lean volunteers (2440 vs. 2730 kJ; P<0.05). Preprandial hunger scores were also lower in the PP group. Notably, these appetite-suppressing effects were achieved at plasma PP levels within the pathophysiological range seen in patients with pancreatic tumors, rather than at the supraphysiological levels used previously.
Why it matters
This study demonstrated that even a low dose of pancreatic polypeptide can meaningfully reduce food intake in humans, strengthening the case that PP functions as a natural satiety signal. It suggested that PP-based therapies might offer a physiologically grounded approach to appetite control, relevant to the growing field of gut peptide-based weight management.
The numbers in context
n=14 · 11% reduction in energy intake · PP 5 pmol/kg/min · 2440 vs 2730 kJ · P<0.05
How the study worked
Randomized, double-blind, placebo-controlled crossover study in 14 lean fasted volunteers (5 men, 9 women). Participants received 90-minute IV infusions of either PP (5 pmol/kg per min) or saline on two separate days. One hour after infusion ended, a buffet lunch was served and energy intake measured. Hunger was assessed using visual analogue scales.
Who was studied
14 lean, healthy fasted volunteers (5 men, 9 women)
What this study cannot tell us
Small sample size of only 14 participants. IV administration is not practical for real-world use. Only lean volunteers were studied — effects in overweight or obese individuals are unknown. Single-meal measurement does not capture longer-term appetite effects. Crossover design helps but the study was still underpowered.
How to read the evidence
This is a randomized, double-blind, placebo-controlled crossover trial in humans, which is a strong design. However, the sample size of 14 is small, it used IV rather than practical delivery, and only measured a single meal outcome, limiting the strength of the conclusions.
When this study was published
Published in 2007, this study is nearly two decades old. While the basic finding remains valid, the gut peptide field has advanced substantially since then, with GLP-1 agonists becoming the dominant approach to peptide-based appetite control.
The bigger picture
Pancreatic polypeptide belongs to the same family of gut hormones — including GLP-1 and PYY — that pharmaceutical companies have targeted for weight loss drugs. While GLP-1 agonists like semaglutide have become blockbusters, PP remains less explored. This study added evidence that PP is a genuine satiety signal, not just a bystander hormone, keeping it on the map as a potential therapeutic target.
Questions still open
- Would pancreatic polypeptide reduce food intake in overweight or obese individuals, who are the target population for weight management?
- Can PP be delivered in a practical non-IV form, such as nasal spray or long-acting injection, for real-world appetite control?
- How does PP's appetite-suppressing effect compare or combine with other gut peptides like GLP-1 and PYY?
Common questions
What is pancreatic polypeptide and what does it do?
Could pancreatic polypeptide become a weight loss drug?
Read the original research
Low-dose pancreatic polypeptide inhibits food intake in man.
The British journal of nutrition, 97(3), 426-9
Citation
Jesudason, David R; Monteiro, Mariana P; McGowan, Barbara M C; Neary, Nicola M; Park, Adrian J; Philippou, Elena; Small, Caroline J; Frost, Gary S; Ghatei, Mohammad A; Bloom, Stephen R. (2007). Low-dose pancreatic polypeptide inhibits food intake in man.. The British journal of nutrition, 97(3), 426-9.